Although AUD and PTSD are a common co-morbidity faced by many Americans, there is currently no medication that helps alleviate the symptoms of both disorders concurrently. This study is a proof-of-concept study that aims to test the effectiveness of the combination of extended-release naltrexone (XR-NTX) and sublingual buprenorphine (SL-BUP) in the treatment of AUD and co-morbid PTSD. Participants enrolled in this 14-week long study will be given treatment for 12 weeks, asked to fill out self-report measures and meet with study personnel to complete interview measures, provide blood and urine samples, and participate in psychophysiological tasks, among other things.  

 

Interested in participating? Click the link below to fill out an interest form, which contains some basic eligibility questions, and a study member will be in touch shortly!

Kappa Opioid Receptor (KOR) Antagonism for the Treatment of Alcohol Use Disorder (AUD) and Co-Morbid Post-traumatic Stress Disorder (PTSD)